Navidea Biopharmaceuticals Incの資産のリターン

Navidea Biopharmaceuticals Incの資産のリターン は何ですか。

Navidea Biopharmaceuticals Incの資産のリターン は-87.38%です。

資産のリターン の定義は何ですか。



資産のリターンは 、企業の資産が収益を生み出す際の収益性を示します。純利益を平均総資産で除して計算されます。

The return on assets (ROA) tells you what the company can do with what it has, i.e. how many dollars of earnings they derive from each dollar of assets they control. It's a useful number for comparing competing companies in the same industry. The number will vary widely across different industries. Return on assets gives an indication of the capital intensity of the company, which will depend on the industry; companies that require large initial investments will generally have lower return on assets. ROAs over 5% are generally considered good.

NYSEMKTのセクタHealth Careにおける資産のリターン の企業と比べるNavidea Biopharmaceuticals Inc

Navidea Biopharmaceuticals Incは何をしますか。

navidea biopharmaceuticals, inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. it operates through two segments, diagnostic substances and therapeutic development programs. the company develops manocept platform to target the cd206 mannose receptor expressed on activated macrophages. its cd206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (pet), imaging and topical gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. further, the company offers nav4694, a fluorine-18 labeled pet imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of alzheimer's disease and mild cognitive impairment. in addition, it is de

Navidea Biopharmaceuticals Incと類似の資産のリターン